Growth in the broader peptide market does not indicate that the Company will capture any portion of it
Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
Any patient experiencing blood in stool should seek prompt clinical assessment to determine the underlying cause and ensure appropriate management
Speaking with a medical professional as it relates to your individual health history will help to assess whether semaglutide is the best treatment option for you
Why is 4 - pl curve fitting is required for generating standard curve
(1990) and Knivsberg et al